Paper - WANFANG MED ONLINE

You Position: Home > Paper

GLP-1受体激动剂/类似物抗血栓形成作用的研究进展

( views:65, downloads:120 )

Author:: No author available

Journal Title:: China Clinical Practical Medicine

Issue:: 6

DOI:: 10.3760/cma.j.issn.1673-8799.2018.06.023

Key Word:: 肠促胰素;胰高血糖素样肽1;血小板;血栓;心血管事件

Abstract：肠促胰素包括胰高血糖素样肽1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂.其中GLP-1是通过胰高血糖素原基因产物的翻译后蛋白水解切割产生的,在肠L细胞远端分泌.越来越多的研究表明,GLP-1受体激动剂/类似物除了具有减轻体质量、降低血压、改善血脂、抑制炎症因子、改善内皮功能外,还具有抗血栓形成、延缓动脉粥样硬化进展、保护心血管的作用.因此,我们对GLP-1受体激动剂/类似物潜在的抗血栓形成作用及其相关因子综述如下.

Reference

[1]高维鸿,蔡祥胜,谭照光,等.胰高血糖素样肽-1改善过氧化氢诱导的血管内皮氧化损伤[J].2017,(1).
[2]Zheng S,Yang Q,Sabo M,etc.GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.[J].2005,288(5).
[3].Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage[J].2012,32(12).
[4]Parlevliet ET,Picha K,Pijl H,etc.CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.[J].2009,328(1).
[5]Nystrom T,Sjoholm A.Inflammation and the etiology of type 2 diabetes.[J].2006,22(1).
[6]Wang,Y.,Parlevliet,E.T.,Geerling,J.J.,etc.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration[J].2014,171(3).
[7]Tatiana E, Suslova,Alexei V, Sitozhevskii,Oksana N, Ogurkova,etc.Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation.[J].2014,5.
[8]Dahly A,Yu M,Ditter K,etc.Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.[J].2003,21(6).
[9]Matthias Oelze,Huige Li,Michael Hausding,etc.Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.[J].2015,110(2).
[10]Louise E Robinson,Tim A Holt,Karen Rees,etc.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis[J].2013,3(1).
[11]Nauck, Michael,Frid, Anders,Hermansen, Kjeld,etc.Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes.[J].2009,32(1).
[12]Bunck MC,Diamant M,Eliasson B,etc.Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.[J].2010,33(8).
[13]Cameron-Vendrig,A.,Mundil,D.,Husain,M..Antiatherothrombotic effects of dipeptidyl peptidase inhibitors[J].2014,16(5).
[14]Aroor,A.R.,Sowers,J.R.,Bender,S.B.,etc.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats[J].2013,154(7).
[15]Adeli K,Hsieh J,Baker CL,etc.The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.[J].2010,53(3).
[16]H?lscher,C.,Parthsarathy,V..The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain[J].2013,700(1).
[17]Y Kang,H-S Jun,S-S Kim,etc.Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.[J].2012,55(9).
[18]W B, Kannel,C, Kannel,R S, Paffenbarger,etc.Heart rate and cardiovascular mortality: the Framingham Study.[J].1987,113(6).
[19]Wang,B.,Zhong,J.,Lin,H.,etc.Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials[J].2013,15(8).
[20]Diamant M,Van Gaal L,Stranks S,etc.Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.[J].2010,375(9733).
[21]Michelle A Corrigan,Donal O'Shea,Lydia Lynch,etc.Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.[J].2014,57(4).
[22]Yong Zhang,Jizhong Lou.GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice.[J].2012,7(11).
[23]Chiang-Ting Chien,Shih-Chen Fan,Shao-Chieh Lin,etc.Glucagon-like.peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure In chronic kidney disease[J].2014,112(5).
[24]Mylotte,D.,Kenny,D.,Tedesco,A.F.,etc.Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control[J].2012,23(6).
[25]THE MACB STUDY GROUP.Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting[J].1995,16(12).
[26]Mei-Yueh, Lee,Kun-Bow, Tsai,Jong-Hau, Hsu,etc.Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.[J].2016.
[27]Madsen AN,Hansen G,Paulsen SJ,etc.Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.[J].2010,206(3).
[28]Grakoui A,Gupta NA,Handy J,etc.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.[J].2010,51(5).
[29]Barale, Cristina,Buracco, Simona,Cavalot, Franco,etc.Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation[J].2017,117(6).
[30]Catarina Marques,Cristina Mega,Andreia Goncalves.Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals[J].2014,2014(Pt.3).
[31].Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: Ameta-analysis of randomized clinical trials[J].2013,15(2).
[32]Grobbee DE,Kok FJ,Stam BE,etc.Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.[J].2003,42(5).
[33]Dear AE,Simpson RW,Knudsen LB,etc.A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.[J].2009,201(1).
[34]Ban K,Hoefer J,Drucker DJ,etc.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.[J].2008,117(18).
[35]Monami,M.,Dicembrini,I.,Nardini,C.,etc.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: A meta-analysis of randomized clinical trials[J].2014,16(1).
[36]Steven Sebastian,Jurk Kerstin,Kopp Maximilian,etc.Glucagon‐like peptide‐1 receptor signalling reduces microvascular thrombosis, nitro‐oxidative stress and platelet activation in endotoxaemic mice[J].2017,174(12).
[37]Xing-Chun Wang,Aaron M Gusdon,Huan LIU,etc.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation[J].2014,(40).
[38]Maseri Attilio,Libby Peter,Ridker PaulM.Inflammation and atherosclerosis.[J].2002,105(9).
[39]Vitoon Saengsirisuwan,Betsy B. Dokken,Erik J. Henriksen,etc.Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3[J].2008,294(3 Pt.1).
[40]Dash,S.,Bandsma,R.H.J.,Xiao,C.,etc.Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans[J].2012,32(6).
[41]Cameron-Vendrig, Alison,Reheman, Adili,Siraj, M. Ahsan,etc.Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis[J].2016,65(6).
[42]Hulmi,J.J.,Silvennoinen,M.,Lehti,M.,etc.Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy[J].2012,302(3 Pt.1).
[43]Gallwitz B,Vaag A,Falahati.Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.[J].2010,64(2).
[44]Dominick J. Angiolillo,Esther Bernardo,Manel Sabaté,etc.Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[J].2007,50(16).